Peficitinib hydrobromide
Peficitinib hydrobromide Basic information
- Product Name:
- Peficitinib hydrobromide
- Synonyms:
-
- Peficitinib hydrobromide (JAN/USAN)
- Peficitinib hydrobromide
- 4-(5-Hydroxytricyclo3.3.1.13,7dec-2-yl)amino-1H-pyrrolo2,3-bpyridine-5-carboxamide hydrobromide (1:1) stereoisomer
- Peficitinib Hydrobromid
- anti-4-((5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide
- CAS:
- 1353219-05-2
- MF:
- C18H22N4O2. HBr
- MW:
- 407.31
- Mol File:
- 1353219-05-2.mol
Peficitinib hydrobromide Chemical Properties
- InChI
- InChI=1S/C18H22N4O2.BrH/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10;/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22);1H
- InChIKey
- ZUVPMAPXNYGJQC-UHFFFAOYSA-N
- SMILES
- N(C1C(=CN=C2NC=CC=12)C(=O)N)C1C2CC3CC(O)(C2)CC1C3.Br
Peficitinib hydrobromide Usage And Synthesis
Uses
Peficitinib (ASP015K) hydrobromide is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1].
Mechanism of action
Peficitinib hydrobromide potently inhibits the JAK-STAT pathway and blocks the signaling of pro-inflammatory cytokines such as IL-6 and IFN-γ. It has the strongest inhibitory activity against JAK3 (IC₅₀ = 0.7 nM), while also taking into account other subtypes (JAK1/2/Tyk2 IC₅₀ 3.9–5.0 nM).
Synthesis
Synthesis of Peficitinib hydrobromide
in vivo
Peficitinib hydrobromide (1-30 mg/kg; p.o.; once daily for 24 days) shows dose-dependent efficacy both in prophylactic and therapeutic dosing regimens in an adjuvant-induced arthritis rat model[1].
| Animal Model: | Seven-weeks-old female Lewis rats, adjuvant-induced arthritis (AIA) model[1] |
| Dosage: | 1, 3, 10, and 30 mg/kg |
| Administration: | Oral administration, once daily for 24 days |
| Result: | Significantly inhibited the increase in paw volume at doses of 1 mg/kg or greater with an ED50 value of 2.7 mg/kg (95% confidence interval: 1.5–4.2 mg/kg). Significantly reduced the bone destruction score at 10 mg/kg or greater and almost fully ameliorated both paw swelling and bone destruction scores at 30 mg/kg. |
IC 50
JAK3: 0.7 nM (IC50); JAK1: 3.9 nM (IC50); Tyk2: 4.8 nM (IC50); JAK2: 5 nM (IC50)
References
[1] Ito M, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017 Jan;133(1):25-33. DOI:10.1016/j.jphs.2016.12.001
Peficitinib hydrobromideSupplier
- Tel
- +21-18501659228 18501659228
- info@hope-chem.com
- Tel
- 18118984557; 18118984557
- 753016615@qq.com
- Tel
- 18908011947
- 3903467217@qq.com
- Tel
- 025-58741518 13327700685
- sales@vcarepharmatech.com
- Tel
- 0317-5296180 15533709196
- sale@enkepharma.com